Nuveen
HRTX icon

Nuveen’s Heron Therapeutics HRTX Stock Holding History

Nuveen’s Portfolio HRTX Stock Details HRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$94.7K Sell
221,787
-304,506
-58% -$244K ﹤0.01% 3710
2026
Q1 		$421K Buy
526,293
+179,228
+52% +$208K ﹤0.01% 2906
2025
Q4 		$451K Hold
347,065
– – ﹤0.01% 2913
2025
Q3 		$437K Hold
347,065
– – ﹤0.01% 2942
2025
Q2 		$718K Buy
347,065
+32,790
+10% +$67K ﹤0.01% 2759
2025
Q1 		$691K Hold
314,275
– – ﹤0.01% 2791
2024
Q4 		$481K Sell
314,275
-792,421
-72% -$1.28M ﹤0.01% 2999
2024
Q3 		$2.2M Sell
1,106,696
-73,532
-6% -$176K ﹤0.01% 2370
2024
Q2 		$4.13M Buy
1,180,228
+85,541
+8% +$263K ﹤0.01% 2049
2024
Q1 		$3.03M Buy
1,094,687
+1,002,935
+1,093% +$2.52M ﹤0.01% 2204
2023
Q4 		$156K Hold
91,752
– – ﹤0.01% 3245
2023
Q3 		$94.5K Hold
91,752
– – ﹤0.01% 3129
2023
Q2 		$106K Sell
91,752
-629,279
-87% -$1.12M ﹤0.01% 3159
2023
Q1 		$1.09M Buy
721,031
+436,516
+153% +$1.09M ﹤0.01% 2581
2022
Q4 		$712K Sell
284,515
-2,765
-1% -$8.91K ﹤0.01% 2803
2022
Q3 		$1.21M Sell
287,280
-639
-0.2% -$2.5K ﹤0.01% 2658
2022
Q2 		$804K Sell
287,919
-271,153
-49% -$1.09M ﹤0.01% 2888
2022
Q1 		$2.86M Sell
559,072
-161,797
-22% -$1.18M ﹤0.01% 2348
2021
Q4 		$6.1M Sell
720,869
-28,041
-4% -$286K ﹤0.01% 2007
2021
Q3 		$9.06M Sell
748,910
-75,403
-9% -$918K ﹤0.01% 1846
2021
Q2 		$12.8M Buy
824,313
+333,667
+68% +$5.31M ﹤0.01% 1698
2021
Q1 		$7.95M Buy
490,646
+46,111
+10% +$822K ﹤0.01% 1922
2020
Q4 		$9.41M Sell
444,535
-317,830
-42% -$5.52M ﹤0.01% 1741
2020
Q3 		$11.3M Sell
762,365
-121,985
-14% -$1.9M ﹤0.01% 1446
2020
Q2 		$13M Buy
884,350
+46,816
+6% +$769K 0.01% 1306
2020
Q1 		$9.83M Buy
837,534
+126,654
+18% +$2.38M ﹤0.01% 1300
2019
Q4 		$16.7M Buy
710,880
+323,639
+84% +$7.16M 0.01% 1272
2019
Q3 		$7.16M Buy
387,241
+1,594
+0.4% +$29.3K ﹤0.01% 1762
2019
Q2 		$7.17M Buy
+385,647
New +$7.7M ﹤0.01% 1796

Other funds holding HRTX

RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
CC
Clearline Capital New York $1.68B AUM 53.07% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VCIM
Velan Capital Investment Management Alpharetta, Georgia $164M AUM 542.31% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
TC
Tejara Capital London, United Kingdom $243M AUM 9.84% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
JAM
JW Asset Management Miami Beach, Florida $320M AUM 140.1% 1-Year Est. Return

Nuveen's HRTX Position: Q2 2026 in Review

Nuveen reduced its Heron Therapeutics (HRTX) stake by 58% in Q2 2026, selling an estimated $244K and leaving 221,787 shares worth $94.7K. The position accounts for ﹤0.01% of the portfolio, ranked #3710.

Nuveen first reported a position in HRTX in Q2 2019 and has held it in 29 quarters since. The position peaked at $16.7M in Q4 2019. 163 funds tracked by Wall St. Rank hold HRTX as of Q2 2026.

  • Nuveen held 221,787 shares of Heron Therapeutics worth $94.7K as of Q2 2026.
  • Nuveen sold 304,506 Heron Therapeutics shares in Q2 2026, an estimated $244K.
  • Heron Therapeutics made up ﹤0.01% of Nuveen's portfolio in Q2 2026, its #3710 holding.
  • Nuveen first reported a position in Heron Therapeutics in Q2 2019 and has held it in 29 quarters since.
  • Nuveen's Heron Therapeutics position peaked at $16.7M in Q4 2019.
  • 163 funds tracked by Wall St. Rank held Heron Therapeutics as of Q2 2026.

Based on Nuveen's 13F filing for Q2 2026, filed 11 Aug 2026.